Shanghai Enhances Payment Mechanisms to Drive Pharma and Medical Innovation
Shortly after the National Healthcare Security Administration (NHSA) introduced its more industry-friendly renewal rules for older NRDL-negotiated drugs, the Shanghai
China Implements More Moderate and Predictable Price Reduction for Older NRDL-Negotiated Drugs
In late June, the National Healthcare Security Administration (NHSA) commenced the 2023 National Reimbursement Drug List (NRDL) Dynamic Update, aiming
Behind the Scenes: Exploring the Roadblocks to Formulary Listing for NRDL-Negotiated Drugs in China Public Hospitals
China's National Reimbursement Drug List (NRDL) is increasingly incorporating innovative drugs. Once included in the NRDL, these drugs
Navigating China's Access Landscape for Orphan Therapies: Insights into Funding Pathways
Welcome back to the final installment of our three-part series exploring China's access landscape of rare disease therapies.
Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities
In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations
Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance
In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
